Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 13/20 | 0.46 |
| ▸ | ERBB2 | P04626 | 12/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | DHFR | P00374 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | PCNA | P12004 | 1/20 | 0.43 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.41 |
| ▸ | GLS | O94925 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31023859 | 0.84 | LMNA (0.51) | EGFRERBB2PCNA | |
| SCHEMBL4572811 | 0.83 | PLA2G10 (0.44) | ALDH1A1DHFRTSHRSMN1; SMN2TDP1 | |
| SCHEMBL17127746 | 0.82 | EGFR (0.68) | EGFRERBB2SMN1; SMN2 | |
| SCHEMBL16446138 | 0.81 | MEN1 (0.57) | PDE4BEGFRERBB2ALDH1A1CNR2 | |
| SCHEMBL3978340 | 0.80 | EGFR (0.42) | EGFRERBB2ALDH1A1CNR2DHFR | |
| SCHEMBL7697158 | 0.79 | EGFR (0.67) | EGFRERBB2ALDH1A1SMN1; SMN2TDP1 | |
| SCHEMBL26163119 | 0.78 | EGFR (0.43) | PDE4BEGFRERBB2TDP1PCNA | |
| SCHEMBL1632446 | 0.77 | LMNA (0.51) | ALDH1A1CNR2TSHRTDP1GLS | |
| SCHEMBL21887012 | 0.77 | ALDH1A1 (0.55) | ALDH1A1 | |
| SCHEMBL3975407 | 0.77 | EGFR (0.73) | EGFRERBB2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210340146-A1 | PYRAZOLOPYRIMIDINE COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF IN PREPARATION OF ANTI-CANCER DRUG | SUZHOU RAYMON PHARMACEUTICALS COMPANY LTD (CN) | 2021-11-04 | — | — | US | disclosed |
| WO-2020063636-A1 | PYRAZOLOPYRIMIDINE COMPOUND AND PREPARATION METHOD AND USE THEREOF IN PREPARATION OF ANTI-CANCER DRUG | 苏州锐明新药研发有限公司 | 2020-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210340146-A1 | PYRAZOLOPYRIMIDINE COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF IN PREPARATION OF ANTI-CANCER DRUG | PIK3CA, PIK3CD, PIK3R5 | PDE4B 322/4885EGFR 2362/4885ERBB2 1200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.